Translational Research Projects

The following translational research projects are being carried out by Liver Center members:

Winston Dunn, MD

Donor rs 738409 Genotype Predicts Fibrosis in Liver Transplantation For Hepatitis C

A Randomized, Double-Blind, Controlled, Multi-Center Phase 2 Study to Evaluate the Effect of Roflumilast Plus Pioglitazone on Liver Enzymes and Liver Fat Content in Subjects with Nonalcoholic Steatohepatitis.

Sean Kumer, MD, PhD and Ken Dorko, BS 

Isolation of Human Hepatocytes from Donor Livers Prior to Transplant, and Surgical Discards.

Jody Olson, MD

A Multi-Center Group to Study Acute Liver Failure and Injury at the University of Kansas Medical Center.

Ocera hospitalized hepatic encephalopathy.

Mojtaba Olyaee, MD and Hartmut Jaeschke, PhD

Determination of Bile Acid Concentrations During Acute Cholestasis in Humans. 

Mechanisms of Liver Injury in Patients with Acetaminophen Overdose.

Ryan Taylor, MD

A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection GS-US-248-0122.           

A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead- Sponsored Trials in Subjects with Chronic Hepatitis C Infection  GS-US-248-0123.

Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobavir and Ribavirin (RBV) Compared with GS-5885, GS-9451 with Tegobavir or RBV in Treatment-Experienced Subjects with Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection.

Gilead GS-US-248-0132: A Randomized, Open-Label, Multicenter Study of the Safety, Efficacy, and Tolerability of Combination Treatment of Setrobuvir, Danoprevir, Ritonavir, and Copegus® with or without Mericitabine in HCV Genotype 1-Infected Patients Who are Either Treatment Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment 

GS-US-174-0172 A prospective, Observational, Post-marketing Renal Safety Surveillance in Patients With Chronic Hepatitis B (HBV) Infection With Decompensated Liver Disease Receiving Nucleotide/side Therapy While on the Orthotopic Liver Transplant (OLT) List.

A Randomized, Open-Label, Multicenter Study of the Safety, Efficacy, and Tolerability of Combination Treatment of Setrobuvir, Danoprevir, Ritonavir, and Copegus® with orwithout Mericitabine in HCV Genotype 1-Infected Patients Who are Either Treatment Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment.

A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated with DAA-containing regimens for chronic hepatitis C infection (CHC).

A Phase 2, Multicenter, Randomized, Partially Blind, Dose Ranging    Study to Evaluate the Efficacy and Safety of VX‑135 and Daclatasvir With or Without  Ribavirin for 12 Weeks in Treatment-Naïve Adult Subjects with Genotypes 1, 2, or 3 Chronic Hepatitis C Virus.

Steven Weinman, MD, PhD

Liver Tissue Bank and Procurement

Mechanisms of Liver Injury Related to Alcohol and Hepatitis C 

The Role of Circulating Cancer Progenitor Cells in Recurrence of Hepatocellular Carcinoma After Liver Transplantation.

For more information on these studies or interested in developing a study, please email Brian Bridges or Erin Dunn

Last modified: Oct 30, 2013
ID=x6347